| Abstract: | Objective: To evaluate the actual dosing of etanercept in US commercially insured patients with psoriatic disease, to estimate treatment cost.Methods: This study evaluated medical and pharmacy claims in a US commercial claims database from November 1, 2003 through June 30, 2008. Biologic-naïve patients diagnosed with psoriasis, psoriatic arthritis, or both, who filled prescriptions for etanercept and were enrolled for ≥6 months before the first claim and 1 year after, were included. Patients with rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis during the study period were excluded.Results: Among 2,359 patients, diagnoses included psoriasis (n = 1,810), psoriatic arthritis (n = 212), and both diseases (n = 337). Psoriasis patients used a mean 98% (standard deviation [SD] 28%) and psoriatic arthritis patients used 107% (SD 31%) of label-recommended etanercept doses.Conclusions: Overall, patients with psoriatic disease used 98–104% of the expected etanercept dose, depending on whether the expected dose for patients with both diagnoses was the psoriasis or psoriatic arthritis dose. This study does not evaluate effectiveness or clinicians’ intent and may not be representative of other populations. Nevertheless, average usage was as expected for all cohorts, providing a basis for cost estimation. |
